← SynDRA
CABOTEGRAVIR
SynDRA canonical compound SYN0037442 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Approval status | Approved · Rx |
|---|
| Mechanism of action | HIV integrase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- HIV integrase INHIBITOR
- HIV IN INHIBITOR
- pol INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- AURKA
- BRD4
- BRPF1
- CDK2
- CSNK1D
- CYP3A4
- FGFR2
- GSK3B
- HDAC6
- MAPK1
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- HIV Integrase Inhibitors
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiviral Agents
- Enzyme Inhibitors
- Integrase Inhibitors
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
- Organic Anion Transporter 1 Inhibitors
- Organic Anion Transporter 3 Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- APRETUDE
- Apretude
- CABENUVA KIT
- VOCABRIA
- Vocabria
- cabotegravir sodium
- vocabria
- GSK1265744
- Gsk-1265744
- GSK744
- GSK-1265744A
- GSK1265744A
- S-265744
- Cabotegravir component of cabenuva
- UNII-HMH0132Z1Q
- GSK-1265744
- HMH0132Z1Q
- Cabotegravir (GSK744, GSK1265744)
- CAB
- Cabotegravir [USAN:INN]
- GSK744 LAP
- GSK744 LA
- S/GSK1265744
- GSK 744
- 744 LA
- GSK 1265
- GSK 1265744
- CABENUVA COMPONENT CABOTEGRAVIR
- cabotegravirum
- CHEBI:172944
- RefChem:573195
- Cabotegravir and rilpivirine
- MFCD25976748
- Vocabria (TN)
- C19H17F2N3O5
- Apretude (TN)
- Cabotegravir (Standard)
- Cabotegravir(GSK744)
Reported adverse events
- Hepatotoxicity
- Hypersensitivity
- Abdominal pain
- Anxiety
- Dizziness
- Headache
- Nausea
- Pyrexia
- Rash
- Suicidal ideation
- Fatigue
- Injection site reaction
Look up CABOTEGRAVIR in the interactive SynDRA portal →